Submitted Successfully!
Thank you for your contribution! You can also upload a video entry or images related to this topic.
Ver. Summary Created by Modification Content Size Created at Operation
1 + 3596 word(s) 3596 2021-05-25 10:36:03 |
2 format correct + 1670 word(s) 5266 2021-06-02 04:50:11 |

Video Upload Options

Do you have a full video?


Are you sure to Delete?
If you have any further questions, please contact Encyclopedia Editorial Office.
Shi, L. Rho GTPase Regulators. Encyclopedia. Available online: (accessed on 03 December 2023).
Shi L. Rho GTPase Regulators. Encyclopedia. Available at: Accessed December 03, 2023.
Shi, Lei. "Rho GTPase Regulators" Encyclopedia, (accessed December 03, 2023).
Shi, L.(2021, June 01). Rho GTPase Regulators. In Encyclopedia.
Shi, Lei. "Rho GTPase Regulators." Encyclopedia. Web. 01 June, 2021.
Rho GTPase Regulators

The Rho family GTPases are small G proteins that act as molecular switches shuttling between active and inactive forms. Rho GTPases are regulated by two classes of regulatory proteins, guanine nucleotide exchange factors (GEFs) and GTPase-activating proteins (GAPs). Rho GTPases transduce the upstream signals to downstream effectors, thus regulating diverse cellular processes, such as growth, migration, adhesion, and differentiation. In particular, Rho GTPases play essential roles in regulating neuronal morphology and function. Recent evidence suggests that dysfunction of Rho GTPase signaling contributes substantially to the pathogenesis of autism spectrum disorder (ASD). It has been found that 20 genes encoding Rho GTPase regulators and effectors are listed as ASD risk genes by Simons foundation autism research initiative (SFARI).

Rho GTPase autism spectrum disorder guanine nuclear exchange factor GTPase-activating protein animal model behavior

1. Introduction

Autism spectrum disorder (ASD) is a neurodevelopmental disorder characterized by two core symptoms: (1) impaired social interaction and communication, and (2) repetitive or restricted interest and behaviors. The average global prevalence of ASD is ~0.62% [1], and studies in Europe and Asia have identified individuals with ASD with an average prevalence between 1% and 2% [2][3][4][5][6]. Statistics from CDC (Centers for Disease Control and Prevention)’s Autism and Developmental Disabilities Monitoring (ADDM) Network revealed that one in 59 children were diagnosed with ASD in United States in 2018 [7]. In addition, there is a high rate of co-occurring mental health disorders in ASD patients [8]. Meta-analysis of twin studies show that monozygotic twins have significantly higher concordance rate of ASD than dizygotic twins [9][10], thus the aetiology of ASD is closely related to genetic component. However, the genetic causes of ASD are very complex as a huge number of genes contribute to the pathogenesis of ASD. Therefore, databases of ASD-related genes, such as SFARI (Simons foundation autism research initiative) Gene [11][12] and AutDB (the autism gene database) [13], have been established. With the development of genome sequencing, increasing genes related to ASD have been identified. As of November 2019, more than 800 genes have been included in SFARI Gene [14] and more than 1000 genes have been listed in AutDB [15]. Among these ASD susceptibility genes, many converge on synapse regulation such as the regulation of development and maturation of synaptic contacts and synaptic transmission [16][17][18].
In the nervous system, precise neuronal connectivity depends on synapses. It is well known that dendritic spines, which are enriched with filamentous actin, are dynamic structures important for synapse formation, function and plasticity [19]. Rho family GTPases are key regulators of the actin cytoskeleton that play critical roles in axonal outgrowth, dendritic spine morphogenesis, and synapse formation [20]. The Rho family GTPases, which belong to the Ras superfamily, are small G proteins sized ~20 KDa. Human Rho family GTPases include 20 members that can be classified into eight groups [21][22]. By cycling between GTP-bound active forms and GDP-bound inactive forms, Rho GTPases regulate a diverse array of cellular events, including the control of growth, migration, adhesion, and differentiation. Rho GTPase activity is regulated by two different kinds of regulatory protein: guanine nucleotide exchange factors (GEFs), which catalyze the replacement of GDP by GTP, enabling the GTPases to recognize downstream effectors, and GTP-activating proteins (GAPs), which negatively regulate GTPase activity by favoring the GDP-bound forms [19][23]. Rho GTPase activity regulation is a complex process as 82 GEFs [24][25] and 66 GAPs (of which 57 have a common GAP domain) [26] have been identified so far in humans. The complexity of Rho GTPase signaling is also contributed by their downstream effectors, as there are over 70 downstream effectors identified to be capable of transducing signals from Rho GTPases [27].

2. Rho Family GTPases and ASD

Rho GTPases themselves have been rarely reported as risk genes of ASD. The only evidence so far is the linkage of RAC1 with ASD. Rac1 is an important Rho GTPase family member which regulates actin polymerization and spine remodeling through multiple signaling pathways, including PAKs (p21-activated kinases)-LIMK (LIM-domain-containing protein kinase)-cofilin [28], IRSp5 (insulin receptor substrate p53)-WAVE (Wiskott–Aldrich syndrome protein (WASP) family verprolin-homologous protein)-Arp2/3 [29][30], and PKA (protein kinase A) [31]RAC1, encoding RAC1 and RAC1B, is a candidate gene for ASD listed in AutDB. Seven individuals with de novo mutations of RAC1 were identified in patients of developmental disorders with divergent phenotypes [32]. One of these individuals displayed hyperactive behavior, two presented stereotypic movements, and one was diagnosed with autism [32]. Rac1 is highly expressed in embryonic cortex [33], and is ubiquitously expressed in the hippocampus, neocortex, thalamus, and cerebellum [34][35]. Rac1 is essential for the formation of three germ layers during gastrulation [36], and lack of which leads to embryonic lethality in Rac1 knockout (KO) mice. To understand the brain function of Rac1, several Rac1 conditional KO (cKO) mouse models have been constructed and studied. For instance, Foxg1-Cre mediated deletion of Rac1 in the ventricular zone (VZ) of telencephalon [37][38][39], Nkx2.1-Cre-mediated deletion in medial ganglionic eminence (MGE) [40], and Nestin-Cre-mediated deletion in precursors of neurons and glia during early embryonic stage [29] were used to study the important roles of Rac1 for brain development. Moreover, three studies investigated the behavioral changes in Rac1 cKO mouse models. Haditsch and colleagues generated a mouse model in which Rac1 is deleted in pyramidal neurons by Cre under CamKIIα promoter to study the role of Rac1 in memory [41][42]. They demonstrated that loss of Rac1 in the hippocampus impairs long-term potentiation (LTP), and Rac1-deficient mice have impaired spatial memory and working or episodic-like memory [41]. They also found that the impaired working memory in these mice is due to prolonged memory retention or perseveration of the previously learned location [42]. Pennucci and colleagues generated a mouse model named Rac1N mice in which Rac1 is deleted in postmitotic neurons by Synapsin-I-Cre [43]. Rac1N mice show hyperactivity in several exploration tasks, impairment in spatial and working memory, and defects in retaining the context memory [43]. This study also reported failed synchronization of cortical networks in Rac1N mice by quantitative electroencephalogram (EEG). Moreover, spontaneous inhibitory synaptic currents (sIPSCs) are decreased in CA1 glutamatergic pyramidal cells in these mice [43]. However, these findings only focus on memory-related behaviors, but not the typical ASD-related ones such as social behaviors.

3. Rho GTPase Effectors and ASD

It is well known that Rho GTPases act as molecular switches that transduce upstream signals to downstream effectors to engage specific signaling cascades. Once in the GTP-bound active forms, the conformations of effector-binding regions of Rho GTPases are changed to allow interaction with the effectors [44]. This interaction regulates the function of effectors, resulting in a series of cell responses to the initial stimuli. There are a large number of molecules involved in Rho GTPase signaling, and more than 70 proteins have been identified as potential effectors of RhoA, Rac1, and Cdc42 [27]. We examine the overlap between these effector genes and SFARI Gene and find the following six effectors as ASD-risk genes: NCKAP1CYFIP1PAK2ITPR1PRKCA, and WASF1 (Table 1).
Table 1. Rho family GTPases involved in ASD.
ASD Candidate Gene Gene Name Chromosome Location Genetic Category SFARI Gene Score Upstream/DOWNSTREAM Rho GTPase(s)
Rho GTPase GEF
ARHGEF9 Cdc42 guanine nucleotide exchange factor (GEF) 9 Xq11.1-q11.2 Rare Single Gene Mutation, Syndromic Category 1 (High Confidence) CDC42
TRIO Trio Rho guanine nucleotide exchange factor 5p15.2 Rare Single Gene Mutation, Syndromic Category 1 (High Confidence) RHOA, RAC1
DOCK8 Dedicator of cytokinesis 8 9p24.3 Rare Single Gene Mutation Category 2 (Strong Candidate) CDC42
PREX1 Phosphatidylinositol-3,4,5-trisphosphate-dependent Rac exchange factor 1 20q13.13 Genetic Association Category 2 (Strong Candidate) RAC1
ARHGEF10 Rho guanine nucleotide exchange factor 10 8p23.3 Rare Single Gene Mutation, Functional Category 3 (Suggestive Evidence) RHOA
DOCK1 Dedicator of cytokinesis 1 10q26.2 Rare Single Gene Mutation Category 3 (Suggestive Evidence) RAC1
DOCK4 Dedicator of cytokinesis 4 7q31.1 Rare Single Gene Mutation, Genetic Association, functional Category 3 (Suggestive Evidence) RAC1
Rho GTPase GAP
MYO9B Myosin IXB 19p13.11 Rare Single Gene Mutation Category 2 (Strong Candidate) RHOA
OPHN1 Oligophrenin 1 Xq12 Rare Single Gene Mutation, Syndromic Category 2 (Strong Candidate) RHOA, RAC1, CDC42
ARHGAP5 Rho GTPase activating protein 5 14q12 Rare Single Gene Mutation Category 3 (Suggestive Evidence) RHOA, RAC1, CDC42
ARHGAP11B Rho GTPase activating protein 11B 15q13.2 Rare Single Gene Mutation Category 3 (Suggestive Evidence) Unknown
ARHGAP32 Rho GTPase activating protein 32 11q24.3 Rare Single Gene Mutation, Functional Category 3 (Suggestive Evidence) RHOA, RAC1, CDC42
SRGAP3 SLIT-ROBO Rho GTPase activating protein 3 3p25.3 Rare Single Gene Mutation Category 3 (Suggestive Evidence) CDC42, RAC1
OCRL Oculocerebrorenal syndrome of Lowe Xq26.1 Rare Single Gene Mutation, Syndromic Syndromic CDC42, RAC1
Rho GTPase Effector
NCKAP1 NCK-associated protein 1 2q32.1 Rare Single Gene Mutation Category 1 (High Confidence) RAC1
CYFIP1 Cytoplasmic FMR1 interacting protein 1 15q11.2 Rare Single Gene Mutation, Genetic Association, Functional Category 2 (Strong Candidate) RAC1
PAK2 p21 (RAC1) activated kinase 2 3q29 Rare Single Gene Mutation Category 2 (Strong Candidate) CDC42, RAC1
ITPR1 Inositol 1,4,5-trisphosphate receptor type 1 3p26.1 Rare Single Gene Mutation Category 3 (Suggestive Evidence) RHOA
PRKCA Protein kinase C alpha 17q24.2 Rare Single Gene Mutation Category 3 (Suggestive Evidence) RHOA, RAC1, CDC42
WASF1 WAS protein family member 1 6q21 Syndromic Syndromic RAC1

3.1. NCKAP1 (SFARI Gene Score: 1, High Confidence)

Nck-associated protein 1, also known as Nap1, is a component of the WAVE1/2 complex that interacts with activated Rac1 [45]NCKAP1 is located on chromosome 2q32.1. A de novo LGD mutation of NCKAP1 has been identified in ASD probands [46]. Subsequently, several de novo or maternally inherited mutations in NCKAP1 are found in multiple WES studies on ASD probands [47][48][49]. Recently, two studies on Chinese and Caucasian ASD cohorts found more de novo LGD mutations in NCKAP1, which suggests that NCKAP1 is a strong candidate gene for ASD [50][51]. Nap1 does not contain any known functional motif [52] (Figure 1C). Human Nap1 is extensively expressed in multiple tissues except peripheral blood leukocytes, with highest expression detected in the brain, heart, and skeletal muscle [53]. The expression of human Nap1 is ubiquitously observed in all brain regions, with relatively higher levels in the cerebellum, hippocampus, and amygdala [53]. A study reported that human Nap1 is preferentially expressed in neuronal cells and may participate in neuronal apoptotic pathway [53]. Immunoblots from different embryonic ages indicate a pattern of developmentally increased Nap1 expression in the mouse cerebral cortex [54]. Yokota and colleagues found that knockdown of endogenous Nap1 leads to defective neuronal differentiation in mouse cortical neurons [54]. They then generated a Nap1 mutant mouse line in which the N-terminal 898 aa of Nap1 fused with a 1291 aa β-geo reporter is expressed instead of the full-length protein [54]. However, these Nap1 mutant mice are embryonic lethal from E8.5–E10.5 due to neural tube and neuronal differentiation defects [54]. Therefore, mouse models of Nap1 deficiency are still absent for the investigation of Nap1 on regulating neural behaviors.
Figure 1. Schematics of protein domain structures of 20 ASD-related RhoGEFs, RhoGAPs, and Rho effectors. (A) Seven ASD-related RhoGEF protein domain architectures. Arhgef9 (which has two variants, CB I and CB II), Trio, P-Rex1, and Arhgef10 belong to Dbl family, which is characterized by a DH domain (dark violet) and a PH domain (light pink). Dock8, Dock1, and Dock4 belong to Dock family, which contains two main domains, DHR1 domain (dark orchid) and DHR2 domain (dark magenta). (B) Seven ASD-related RhoGAP protein domain architectures. In addition to a common catalytic GAP domain (purple), most RhoGAPs have multiple other functional domains. (C) Six ASD-related Rho effector protein domain architectures. All protein structures are generated using DOG 2.0 (Domain Graph, version 2.0) [55] based on corresponding mouse protein sequences except ARHGAP11B, for which human protein structure is shown as no homologs exist in rodents. Scales represent amino acid numbers of 500. AID, Autoinhibitory Domain; ASH, ASPM/SPD2/Hydin; BAR, Bin/Amphiphysin/Rvs; C1, binding site of diacylglycerol (DAG); C2, binding site of Ca2+; CBR, β-catenin-binding region; CC, coiled-coil; CRAL-TRIO, cellular retinaldehyde-binding protein and TRIO guanine exchange factor; CTR, C-terminal region with proline-rich; DEP, Disheveled, EGL-10, Pleckstrin; DH, Dbl Homology; DHR1, Dock homology region 1; DHR2, Dock homology region 2; F-BAR, Fes-Cip4 homology Bin/Amphiphysin/Rvs; FF, domain with two conserved phenylalanine residues; GAP, GTPase-activating proteins; GBD, guanosine triphosphate (GTP)-binding; GBR, GABARAP-binding region; Ig, immunoglobulin; IP4P, inositol polyphosphate 4-phosphatase; IQ, short calmodulin-binding motif containing conserved isoleucine and glutamine residues; PBD, p21-binding domain; PDZ, PSD95/SAP90, DlgA, ZO-1; pG1, pseudoGTPase domain 1; pG2, pseudoGTPase domain 2; PH, Pleckstrin-Homology; PIX, Pak-interacting exchange factor; Pro, proline-rich; PX, phox homology; Scar, Scar homology; SH3, Src homology 3; WH, WASF homology.

3.2. CYFIP1 (SFARI Gene Score: 2, Strong Candidate)

Cytoplasmic FMR1 interacting protein 1 (Cyfip1), also named Shyc and Sra1, is a Rac1-interacting protein and a partner of the WAVE complex that regulates actin filament. CYFIP1 is located on chromosome 15q11.2. Several studies have reported that patients with 15q11.2 microdeletions and microduplications between breakpoints 1 and 2, which encompass several genes including CYFIP1, are diagnosed with neurodevelopmental disorders including ASD, ID, SCZ, attention-deficit/hyperactivity disorder (ADHD), and obsessive-compulsive disorder (OCD) [56][57][58][59]. A paternally inherited rare variant of CYFIP1 is found in an autistic patient with a de novo SHANK2 deletion [60]. Another paternally inherited rare variant of CYFIP1 is found in a study on high functioning ASD patients [61]. Additionally, SNPs in CYFIP1 were reported to correlate with ASD in two studies [62][63]. A study on CYFIP1 mRNA expression in human dorsolateral prefrontal cortex revealed higher expression of CYFIP1 mRNA in ASD and classical autism patients, and identified several common variants of CYFIP1 in these patients [64]. A recent study also demonstrated significant increase in CYFIP1 transcripts in the peripheral blood of ASD patients [65]. All these clinical findings reveal that altered CYFIP1 dosage may contribute to the pathology of ASD. Cyfip1 has been shown to interact with Rac1, Fragile X mental retardation 1 (FMRP), and eukaryotic translation initiation factor 4E (EIF4E) [66][67] (Figure 1C). Cyfip1 is widely expressed in multiple tissues but not liver during development and is highly enriched in the hippocampus, cerebral cortex, cerebellum, olfactory bulb, and lateral septum in the adult brain [68]. Levels of Cyfip1 are high in the cortex and cerebellum at the stages of postnatal development, peaked at P23 and slightly decreased afterwards [69].
Four different strategies have been used for generation of Cyfip1 KO mice. However, because Cyfip1 is very important for early embryonic development, none produce homozygous Cyfip1 KO mice. Therefore, Cyfip1 HET mice are used for studying behavioral and neural phenotypes in these studies. The first mouse model was generated by mutagenesis with a gene trap vector inserted into intron 1 of Cyfip1. There are no Cyfip1 KO embryos in breeding [70]Cyfip1 HET mice display normal learning and memory abilities in several memory tests, but show more rapid extinction in inhibitory avoidance test, a test for hippocampus-dependent memory [70] (Table 2Supplementary Table S1, supplementary could be found in These results indicate that the accuracy of memory processing in HET mice is much poorer. Cyfip1 HET mice show increased mGluR-dependent LTD and abnormal presynaptic function in hippocampal slices [70][71]. The second one is generated by deleting exons 4–6 of Cyfip1. Inbreeded from Cyfip1HET mice, fertilized Cyfip1 KO oocytes are detectable in blastocyst stage [72]. The KO embryos can survive until E8.5, but become lethal due to complete developmental failure [72]. The Cyfip1HET mice show absence of interest for social cues and deficits in motor learning [73] (Table 2Supplementary Table S1). The third one is generated by deleting exon 5 of Cyfip1, and the Cyfip1 homozygous KO embryos die before E9.5 [74]. Moreover, the difference between the maternal (m−/p+) and paternal (m+/p−) deficiency of Cyfip1 was investigated. Interestingly, Cyfip1 m−/p+ mice only display hypoactivity, whereas Cyfip1 m+/p− mice display increased freezing in cued fear conditioning and abnormal transitions in zero-maze test [74] (Table 2Supplementary Table S1). Both Cyfip1 m-/p+ mice and Cyfip1 m+/p- mice show reduced field EPSC and increased PPF in hippocampal CA1 region, and enhanced mGluR-dependent LTD is observed in Cyfip1 m+/p- mice hippocampal CA1 neurons [74]. The fourth one is generated by inserting a gene trap cassette between exon 12 and 13 of Cyfip1Cyfip1+/- mice display impaired motor coordination, deficient sensory processing/novelty seeking behavior, reduced PPI, and decreased sensory motor gating [75] (Table 2Supplementary Table S1), recapitulating some ASD and SCZ-like behavioral phenotypes. Cyfip1+/- mice show reduced spontaneous neuronal activity and presynaptic function in cortical slices [75]. Besides the whole-body mutant mice, one Cyfip1 cKO mouse model (Cyfip1NEX cKO mice) has been generated, in which exon 4–6 of Cyfip1 was deleted in forebrain excitatory neurons by NEX-Cre. These mice are viable until adulthood with no obvious abnormalities [76]Cyfip1NEX cKO mice show increased mIPSC amplitude in hippocampal CA1 neurons and display similar deficits in dendrite morphology and spine maturation to those described in Cyfip1 haploinsufficient models [76]. There is also a Cyfip1 mutant rat model generated by CRISPR/Cas9 technology, in which a 4 bp heterozygous deletion is introduced in exon 7 of Cyfip1, causing premature stop of the protein [77]. These Cyfip1 haploinsufficient rats exhibit normal learning ability during all behavioral tests, but show deficits in behavioral flexibility [77] (Table 2Supplementary Table S1). As increased transcript levels of CYFIP1 is found in some ASD patients, two transgenic (Tg) Cyfip1 mouse lines (Tg line 1 and Tg line 2) were generated by overexpressing human CYFIP1. mRNA of human CYFIP1 was increased in the cortex and hippocampus of both Tg lines; Cyfip1 protein is also increased in the two brain regions of Tg line 1 and the hippocampus of Tg line 2, but not in the cortex of Tg line 2 [78]. Behaviorally, Tg line 2 mice display subtle defects of spatial learning memory and obvious increased fear response in contextual and cued fear conditioning test, whereas Tg line 1 mice show normal spatial learning memory and increased freezing only to the tone in the novel context during fear conditioning test [78] (Table 2Supplementary Table S1). However, both Tg lines show no deficits in core ASD-related behaviors such as social and repetitive behaviors [78] (Table 2Supplementary Table S1). Together, Cyfip1 deficient mice or rats recapitulate core features of ASD, whereas Cyfip1 Tg mice may not be appropriate ASD models.
Table 2. Summary of ASD-related behavior tests in Rho guanine nucleotide exchange factor (GEF), GTPase-activating protein (GAP), and effector mouse models.
Gene Mouse Model Core Symptoms Comorbidities Reference
Social Related Behavior Language Communication Repetitive Behavior Anxiety and Depression Learning and Memory Basic locomotion and Motor Coordination Schizophrenia and Epilepsy
Summary of ASD-related behavior tests in Rho GEF mouse models
ARHGEF9 Arhgef9 KO mice * NT 1 NT NT Anxiety ↑ Spatial learning and memory ↓ Activity ⎻ NT [79]
TRIO Emx1-Trio−/− mice # NT NT NT NT Spatial learning and memory ↓
Fear memory ↓
NT NT [80]
NEX-Trio+/− mice & Social preference ↓ NT Nestlet shredding (M2, ↑; F3, ⎻) Anxiety ↑
Depression ⎻
Object recognition memory ⎻ Activity ↓
Motor coordination ↓
Prepulse inhibition ⎻ [81]
NEX-Trio−/− mice & Social preference ↓ NT Nestlet shredding (M, ↑; F, ⎻) Anxiety (M, ↑; F, ⎻)
Depression ↑
Object recognition memory ⎻ Activity ↑
Motor coordination ↓
Prepulse inhibition (M, ↓; F, ⎻)
PREX1 Prex1−/− mice * Social preference ↓
Social learning and memory ↓
Olfactory function ⎻
Ultrasonic vocalizations (pup) ↓ Grooming ↑ Anxiety ⎻ Reversal learning ↓
Fear memory ↓
Object recognition memory ⎻
Activity ⎻
Motor coordination ⎻
Prepulse inhibition ⎻ [82]
ARHGEF10 Arhgef10 KO mice * Sociability and social novelty preference ↓ NT NT Anxiety ↓
Depression ↓
Spatial learning and memory ⎻ Activity ↑ Prepulse inhibition ⎻ [83]
DOCK4 Dock4 KO mice & Social novelty preference ↓ Ultrasonic vocalizations (pup) ↓ Stereotyped circling (~9% F; M, ⎻)
Marble burying (M, ⎻; F, NT)
Grooming (M, ⎻; F, NT)
Anxiety ↑ Object recognition memory (F, ↓; M, ⎻)
Spatial memory (M, ↓; F, ⎻)
Working memory (M, ↓; F, ⎻)
Activity (~9% F, ↑; M, ⎻) NT [84]
Dock4 HET mice & Social novelty preference
(F,↓; M, ⎻)
Ultrasonic vocalizations (pup) ⎻ Stereotyped circling (~1.7% F; M, ⎻)
Marble burying (M, ⎻; F, NT)
Grooming (M, ⎻; F, NT)
Anxiety ⎻ Object recognition memory ⎻
Spatial memory (F, ↓; M, ⎻)
Working memory ⎻
Activity (~1.7% F,↑; M, ⎻) NT
Summary of ASD-related behavior tests in Rho GAP mouse models
OPHN1 Ophn1-/y mice * Aggressivity ↓
Social memory ⎻
Olfactory function ↓
NT NT Anxiety ⎻ Working, object recognition, and spatial learning and memory ↓
Fear memory extinction ↓
Vicarious trial and error (VTE) behavior ↓
Activity ↑
Motor coordination ⎻
Behavioral lateralization ↓
NT [85][86][87][88][89]
ARHGAP32 PX-RICS−/− mice (M were used in most behavior tests unless otherwise stated) Social novelty preference ↓
social interaction ↓
Ultrasonic vocalizations (M and F,↓) Grooming ↑
Marble burying ↑
NT Reversal learning ↓
Fear memory ↓
Motor coordination ↓ Epilepsy (Severe progressive seizures) [90][91]
PX-RICS+/− mice (M were used in most behavior tests unless otherwise stated) Social novelty preference ↓
social interaction ↓
Ultrasonic vocalizations (M and F, ⎻) Grooming ⎻
Marble burying ↑
NT Reversal learning ⎻ Motor coordination ⎻ NT [90]
SRGAP3 WRP−/− mice & NT NT NT Anxiety ⎻ Object recognition and long-term memory ↓
Spatial and reversal learning ↓
Working memory ⎻
Activity ⎻
Motor coordination ⎻
NT [92]
WRP+/− mice & NT NT NT Anxiety ⎻ Object recognition and long-term memory ↓
Spatial and reversal learning ↓
Working memory ⎻
Activity ⎻
Motor coordination ⎻
SrGAP3-/- mice & Social interaction ↓ NT Marble burying (M, ⎻; F, NT) Anxiety ⎻ Working memory ↓
Spatial and object recognition memory ⎻
Fear memory ↑
Activity (M,↓; F, ⎻) Prepulse inhibition (F,↓; M, ⎻) [93][94]
OCRL Ocrl1−/y mice * NT NT NT NT Passive avoidance preference ⎻ Activity ⎻
Motor coordination ↓
NT [95]
Ocrl1−/y mice * (Inpp5b deleted but human INPP5B overexpressed) Social preference ⎻
Social novelty ⎻
NT NT NT Spatial learning and memory ⎻ Activity ↓ NT [96]
Summary of ASD-related behavior tests in Rho effector mouse models
CYFIP1 Cyfip1 HET mice * Social interaction ⎻ NT NT Anxiety ⎻ Hippocampus-dependent memory ↓
Working, spatial, and fearing memory ⎻
Activity ⎻ Prepulse inhibition ⎻ [70]
Cyfip1HET mice # Social interest ↓ Ultrasonic vocalizations ⎻ Marble burying ⎻ NT NT Activity ⎻
Motor coordination ↓
NT [73]
Cyfip1 m+/p− (Paternal origin) and Cyfip1 m−/p+ (maternal origin) mice # NT NT NT Anxiety-like behavior Fear memory (m+/p−, ↑; m−/p+, ⎻) Activity (m+/p−, ⎻; m−/p+, ↓) NT [74]
Cyfip1+/− mice * NT NT Self-grooming ⎻
Marble burying ⎻
NT Spatial memory and flexibility ⎻
Object recognition memory ↓
Working memory ⎻
Activity ⎻
Motor coordination ↓
Prepulse inhibition ↓ [75]
Cyfip1+/− rat * NT NT NT NT Behavioral flexibility ↓ NT NT [77]
Human CYFIP1 overexpressing mice (Tg line 1 and Tg line 2) & Social preference ⎻ Ultrasonic vocalizations ⎻ Grooming ⎻
Digging ⎻
Anxiety ⎻ Fear memory (Line 1 and line 2, ↑)
Spatial learning memory (Line 2, ↓; line 1, ⎻)
Working memory (M and F of both lines, ⎻)
Activity ⎻ Prepulse inhibition ⎻ [78]
PAK2 PAK2+/− mice * Social preference ↓
Social memory ↓
Ultrasonic vocalizations ⎻ Marble burying ↑
Grooming ↑
Anxiety ⎻ Spatial learning and memory ⎻ Activity ⎻ Prepulse inhibition ⎻
Acoustic startle response ⎻
ITPR1 IP3R1+/− mice& NT NT NT NT NT Activity ⎻
Motor coordination ↓
NT [98]
L7-CreItpr1flox/flox mice # NT NT NT NT NT Motor coordination ↓ NT [99]
Wnt1-CreItpr1flox/flox mice # NT NT NT NT NT Motor coordination ↓ NT [100]
WASF1 WAVE-1 KO mice # NT NT NT Anxiety ↓ Spatial learning and memory ↓
Object recognition memory ↓
Passive avoidance ⎻
Activity ↓
Motor coordination ↓
NT [101]
WAVE-1 HET mice # NT NT NT Anxiety ⎻ Learning and memory ⎻ Activity ↓
Motor coordination ↓
*: Only male were used in behavior tests; &: Both male and female mice were used in behavior tests; #: Mice gender was not mentioned; 1 NT: not tested; 2 M: male mice; 3 F: female mice;↑ is increased and ↓ is decreased; − is no change; More detailed information is shown in Supplementary Table S1.
As increased mGluR activation was caused by Cyfip1 deficiency, mGluR1 inhibitor LY367385 and mGluR5 antagonist MPEP (2-Methyl-6-(phenylethynyl) pyridine) were used together. Indeed, these mGluR blockers normalized the mGluR-LTD to control levels in hippocampal slices of Cyfip1 HET mice [70] (Table 3). However, the effect of these two inhibitors on behaviors has not been investigated. For non-pharmacological therapeutic approaches, motor training increased the number of newly formed dendritic spines in both WT and Cyfip1HET mice, and the motor learning deficits in Cyfip1HET mice can be alleviated by the behavioral training in early development but not in adult [73] (Table 3).
Table 3. Treatments for Rho GTPase mouse models.
Gene Mouse/Cellular Model Therapeutic Type Therapeutic Strategy Result Reference
TRIO Trio deficient neurons Pharmacological Rp-cAMPS treatment (100 μM) Increased dendritic spine density reversed [81]
Non-pharmacological PDE4A5 overexpression
P-REX1 Prex1-/- mice Pharmacological D-serine (for electrophysiology: 20 μM; for mouse: 0.8 g/kg i.p.(intraperitoneal)) NMDAR-LTD restored; disruptive social novelty corrected [82]
Non-pharmacological WT P-Rex1 or WT Rac1 overexpression (in CA1 pyramidal neurons) NMDAR-LTD restored; disruptive social novelty and reversal learning corrected
DOCK4 Dock4 KO mice Pharmacological D-cycloserine (DCS, 20 mg/kg i.p.) Social novelty restored [84]
Non-pharmacological WT Rac1 overexpression (in CA1 region) Social novelty and synapatic transmission (mEPSC and LTP) restored
Dock4 knockdown neurons Non-pharmacological WT Rac1 overexpression Decreased dendritic spine density reversed [102]
OPHN1 Ophn1-/y mice Pharmacological Rp-cAMPS (bilaterally infused into PFC; 10 μg/μL; 300–400 nl) Cognitive dysfunction in Y-maze ameliorated [89]
Fasudil (dissolved in daily drinking water at 0.65 mg/mL for 3 weeks) Spine morphology in olfactory bulbs, frequency and amplitude of mIPSC in olfactory neurons, and olfactory behaviors rescued [87]
Fear memory extinction restored [88]
Fasudil (orally a daily dose of 3 mg for 3 months) Locomotor activity and object recognition memory restored; abnormal brain morphology ameliorated [86]
ARHGAP32 PX-RICS-/- mice Pharmacological Clonazepam (CZP, 0.03 mg/kg i.p.) Deficits of social preference, reversal learning, and cued fear learning memory reversed [90][91]
CYFIP1 Cyfip1 HET mice hippocampal slices Pharmacological LY367385 (100 μM) and MPEP (2-Methyl-6-phenylethynyl pyridine), (10 μM) (Incubated in slices) mGluR-LTD normalized to control levels [70]
Cyfip1HET mice Non-pharmacological Motor training (at postnatal days 40, 50, and 51) Motor deficits alleviated [73]
PAK2 Pak2+/- mice Non-pharmacological p-cofilin peptide (15 pmol/g i.v. (intravenous)) Social behaviors moderately improved [97]
ITPR1 Wnt1-Cre;Itpr1flox/flox mice Pharmacological CNQX (5 mM; infused into the cerebellum; 0.5 μL/min for 20 min) Dyskinesia ameliorated [100]
Non-pharmacological Mating with Lurcher mice (GluD2LC/+) Dystonic movements eliminated

3.3. PAK2 (SFARI Gene Score: 2, Strong Candidate)

P21 activated kinase 2 (Pak2), activated by Rac1 and Cdc42, is a member of the group I PAK family that belongs to a family of serine/threonine kinases. PAK2 is located on chromosome 3q29, which is classified as one of six strong autism risk loci [103]. A study on six patients of 3q29 microdeletion syndrome identified a ~1.5 Mb microdeletion, which includes entire PAK2. Two of these patients displayed autistic features [104]. Another study on two patients of 3q29 microdeletion syndrome with common ID, a history of autism, and other psychiatric symptoms also reported the same length deletion [105]. In a subsequent study, 11 of 44 patients with 3q29 microdeletion syndrome were found to display diverse neurodevelopmental disorders including autism [106]. Moreover, one de novo copy-number deletion containing PAK2 was found in patients with ASD from the Simons Simplex Collection, and one de novo nonsense mutation and two inherited missense mutations were also found in PAK2 in 914 Han Chinese patients with ASD [97]. All these four studies reveal that PAK2 is a strong candidate for ASD. Pak2 has several recognized domains including two proline-rich regions and an AID (Autoinhibitory Domain) overlapping the PBD (p21-binding domain) in the N-terminal region, a kinase domain at the C-terminus, an acidic region, and a PIX (Pak-interacting exchange factor) binding site [107][108][109] (Figure 1C). Pak2 is ubiquitously expressed in multiple tissues [110]. Human PAK2 shows high expression levels in the brain during the fetal period and low levels after birth. Mouse Pak2 is also down-regulated at the postnatal development in the cortex [97]. Loss of Pak2 leads to embryonic lethality at ~E8 [110][111][112]. Therefore, a recent study used Pak2+/- mice to investigate the behavioral and neural functional changes caused by Pak2 haploinsufficiency. This study revealed that Pak2+/- mice display repetitive and stereotyped behaviors, impaired social interaction, social avoidance, reduced social preference index, and disruptive social memory [97] (Table 2Supplementary Table S1). Pak2+/- mice also exhibit decreased LTP in hippocampal CA1 region neurons [97]. Mechanistically, phosphorylation of both LIMK1, a major downstream target of group I PAKs, and its substrate cofilin were markedly decreased, suggesting abnormal LIMK1/cofilin-mediated actin polymerization in adult Pak2+/- mice cortex [97]. To normalize endogenous p-cofilin levels in the cortex and hippocampus, a p-cofilin peptide was intravenously injected into adult Pak2+/- mice as a substrate to compete with endogenous p-cofilin for phosphatases. As a result, this peptide moderately improved social behaviors but not repetitive behaviors in adult Pak2+/- mice [97] (Table 3).

3.4. ITPR1 (SFARI Gene Score: 3, Suggestive Evidence)

Inositol 1,4,5-trisphosphate receptor type 1, also known as IP3R1, is a RhoA effector. IP3R1 is a member of IP3Rs, which are Ca2+ release channels on the endoplasmic reticulum. ITPR1 is located on chromosome 3p26.1. Three de novo missense variants in ITPR1 are found in ASD probands from WES studies [47][50][48]. In addition, a study on autism risk genes in probands from the Autism Clinical and Genetic Resources in China (ACGC) identified one maternally and one paternally inherited missense variant of ITPR1 [113], and another variant is found in patients with NDDs [114]. IP3R1 has three main domains including a large N-terminal IP3-binding domain, a short C-terminal hydrophobic domain, and an intervening regulatory domain [115] (Figure 2C). The expression of IP3R1 is increased during embryogenesis [116]. Moreover, IP3R1 is predominately expressed in the nervous system [117][118] and is expressed in a wide range of brain regions including the cerebellum, cerebral cortex, hippocampus, olfactory bulb, globus pallidus, and striatum [117]. It was reported that homozygous IP3R1-deficient mice mostly die during the embryonic stage, and the born mice have severe ataxia and seizures and die at around P21 [119]IP3R1+/- mice also show deficits in motor coordination [98] (Table 2Supplementary Table S1). To study the neural function of IP3R1, several IP3R1 brain cKO mouse lines have been generated. A study reported that L7-Cre;Itpr1flox/flox mice, in which Itpr1 is deleted in Purkinje cells, exhibit cerebellar ataxia at around 6 weeks and severe ataxia at 8 weeks after birth [99] (Table 2Supplementary Table S1). L7-Cre;Itpr1flox/flox mice could survive to adulthood, but display abnormal motor learning ability [99] (Table 2Supplementary Table S1). In another study, three cKO lines were used, in which Itpr1 deletion was restricted to the cerebral cortex and hippocampus (Emx1-Cre;Itpr1flox/flox mice), the cerebellum and brainstem (Wnt1-Cre;Itpr1flox/flox mice), and the caudate putamen and globus pallidus (Gpr88-Cre;Itpr1flox/flox mice) [100]. The Emx1-Cre;Itpr1flox/flox mice and Gpr88-Cre;Itpr1flox/flox mice were born normally and showed normal growth patterns until adulthood, without apparent dyskinesia like total Itpr1-/- mice. However, Wnt1-Cre;Itpr1flox/flox mice began to show ataxia at around P9, and exhibited dyskinesia from 2 weeks after birth [100] (Table 2Supplementary Table S1). Wnt1-Cre;Itpr1flox/flox mice show abnormal cerebellar Purkinje cell (PC) firing patterns, due to altered PC activity [100]Itpr1 deficiency induces a series of abnormal electrophysiological features, including failed LTD in the PCs [120], and excessive LTP induction, attenuated depotentiation and LTP suppression, and altered presynaptic activity in hippocampal CA1 neurons [121][122]. However, typical ASD-related behaviors such as social and repetitive behaviors have not been investigated using these mice.
As enhanced PC activity and dystonia were observed in Wnt1-Cre;Itpr1flox/flox mice, pharmacological inactivation of cerebellar activity by AMPA receptor antagonist (CNQX) infusion was examined for therapeutic effects. Indeed, CNQX ameliorates the dyskinesia in these mice [100] (Table 3). Furthermore, dystonic movements were completely absent in Wnt1-Cre;Itpr1flox/flox mice with genetic deletion of cerebellar PCs, achieved by mating Wnt1-Cre;Itpr1flox/flox mice with Lurcher mice (GluD2LC/+) to kill most of PCs by a mutation of the delta 2 glutamate receptor (GluD2) [100] (Table 3).

3.5. PRKCA (SFARI Gene Score: 3, Suggestive Evidence)

Protein kinase C alpha (PKC-α) is a member of lipid-sensitive serine/threonine protein kinases that regulate various cellular functions including proliferation, migration, adhesion, differentiation, and apoptosis. PKC-α appears to be a common downstream effector of RhoA, Cdc42, Rac1. PRKCA is located on chromosome 17q24.2. In two WES studies, three de novo missense variants in PRKCA were reported in ASD probands [47][48]. PKC-α has a variable regulatory domain at the N-terminus consisting of a C1 domain and a C2 domain, which function as the binding sites of diacylglycerol (DAG) and Ca2+, respectively. PKC-α also has a highly conserved kinase domain at the C-terminus comprised by a smaller ATP-binding loop and a substrate-binding site [123][124] (Figure 1C). PKC-α is ubiquitously expressed in all tissues, including the heart, adrenal gland, testis, lung, kidney, spleen, and liver, and is also widespread in various regions of the brain [125]. PKC-α is enriched in both neuronal and glial cultured cells [125]. A PKC-α KO mouse line has been generated, which appears to be normal with regard to external characteristics, viability, and fertility [126]. However, ASD-related behavioral analysis of these mice has not been reported.

3.6. WASF1 (SFARI Gene Score: S, Syndromic)

The Rac1 effector WAS protein family member 1 (WASF1), also known as WAVE-1/Scar1, is a member of the WASP-family. WASF1 is located on chromosome 6q21. Using exome sequencing and whole-genome sequencing, three de novo truncated mutations of WASF1 were reported in five unrelated individuals, all of whom presented ID with autistic features and seizures [127]. This is the only study so far that has reported the relationship between WASF1 and ASD. WAVE-1 is composed by a Scar homology domain, a basic domain, a proline-rich region, a WASF homology (WH) domain, and an acidic domain [128] (Figure 1C). In human tissues, the expression of WAVE-1 is restricted to the brain [129]. Mouse study reveals that WAVE-1 shows high expression in the hippocampus, cortex, hypothalamus, amygdala, and cerebellum [101][130][131]. Two mouse lines of homozygous Wave1 deletion are reported to be either postnatal lethal [130] or reduced in body size of offspring [101]. Behavioral analysis using Wave1 KO mice (WAVE-1 null mice) generated by the second strategy showed hypoactivity, impaired motor coordination and balance, reduced anxiety levels, and defected spatial, nonspatial, and emotional learning and memory in the mice [101] (Table 2Supplementary Table S1).


  1. Elsabbagh, M.; Divan, G.; Koh, Y.-J.; Kim, Y.S.; Kauchali, S.; Marcin, C.; Montiel-Nava, C.; Patel, V.; Paula, C.S.; Wang, C.; et al. Global Prevalence of Autism and Other Pervasive Developmental Disorders. Autism Res. 2012, 5, 160–179.
  2. Baron-Cohen, S.; Gullon-Scott, F.; Allison, C.; Williams, J.; Bolton, P.; E Matthews, F.; Brayne, C. Prevalence of autism-spectrum conditions: UK school-based population study. Br. J. Psychiatry 2009, 194, 500–509.
  3. Kim, Y.S.; Leventhal, B.L.; Koh, Y.-J.; Fombonne, E.; Laska, E.; Lim, E.-C.; Cheon, K.-A.; Kim, S.-J.; Kim, Y.-K.; Lee, H.; et al. Prevalence of Autism Spectrum Disorders in a Total Population Sample. Am. J. Psychiatry 2011, 168, 904–912.
  4. Kočovská, E.; Biskupstø, R.; Gillberg, I.C.; Ellefsen, A.; Kampmann, H.; Stóra, T.; Billstedt, E.; Gillberg, C. The Rising Prevalence of Autism: A Prospective Longitudinal Study in the Faroe Islands. J. Autism Dev. Disord. 2012, 42, 1959–1966.
  5. Sun, X.; Allison, C.; E Matthews, F.; Sharp, S.; Auyeung, B.; Baron-Cohen, S.; Brayne, C. Prevalence of autism in mainland China, Hong Kong and Taiwan: a systematic review and meta-analysis. Mol. Autism 2013, 4, 7.
  6. Wan, Y.; Hu, Q.; Li, T.; Jiang, L.; Du, Y.; Feng, L.; Wong, J.C.-M.; Li, C.-B. Prevalence of autism spectrum disorders among children in China: a systematic review. Shanghai Arch. Psychiatry 2013, 25, 70–80.
  7. Baio, J.; Wiggins, L.; Christence, D.L.; Maenner, M.J.; Daniels, J.; Warren, Z.; Kurzius-Spencer, M.; Zahorodny, W.; Rosenberg, C.R.; White, T.; et al. Prevalence of Autism Spectrum Disorder Among Children Aged 8 Years—Autism and Developmental Disabilities Monitoring Network, 11 Sites, United States, 2014. MMWR Surveill. Summ. 2018, 67, 1–23.
  8. Lai, M.C.; Kassee, C.; Besney, R.; Bonato, S.; Hull, L.; Mandy, W.; Szatmari, P.; Ameis, S.H. Prevalence of co-occurring mental health diagnoses in the autism population: A systematic review and meta-analysis. Lancet Psychiatry 2019, 6, 819–829.
  9. Colvert, E.; Tick, B.; McEwen, F.; Stewart, C.; Curran, S.R.; Woodhouse, E.L.; Gillan, N.; Hallett, V.; Lietz, S.; Garnett, T.; et al. Heritability of Autism Spectrum Disorder in a UK Population-Based Twin Sample. JAMA Psychiatry 2015, 72, 415–423.
  10. Tick, B.; Bolton, P.; Happé, F.; Rutter, M.L.; Rijsdijk, F. Heritability of autism spectrum disorders: A meta-analysis of twin studies. J. Child Psychol. Psychiatry 2015, 57, 585–595.
  11. Banerjee-Basu, S.; Packer, A. SFARI Gene: An evolving database for the autism research community. Dis. Model. Mech. 2010, 3, 133–135.
  12. Abrahams, B.S.; Arking, D.E.; Campbell, D.; Mefford, H.C.; Morrow, E.M.; Weiss, L.A.; Menashe, I.; Wadkins, T.; Banerjee-Basu, S.; Packer, A. SFARI Gene 2.0: A community-driven knowledgebase for the autism spectrum disorders (ASDs). Mol. Autism 2013, 4, 36.
  13. Basu, S.N.; Kollu, R.; Banerjee-Basu, S. AutDB: A gene reference resource for autism research. Nucleic Acids Res. 2008, 37, D832–D836.
  14. SFARI Gene. Available online: (accessed on 27 March 2020).
  15. AutDB. Available online: (accessed on 27 March 2020).
  16. Ebert, D.H.; Greenberg, M.E. Activity-dependent neuronal signalling and autism spectrum disorder. Nature 2013, 493, 327–337.
  17. Bourgeron, T. From the genetic architecture to synaptic plasticity in autism spectrum disorder. Nat. Rev. Neurosci. 2015, 16, 551–563.
  18. Joensuu, M.; LaNoue, V.; Hotulainen, P. Dendritic spine actin cytoskeleton in autism spectrum disorder. Prog. Neuro-Psychopharmacol. Biol. Psychiatry 2018, 84 Pt B, 362–381.
  19. Tolias, K.F.; Duman, J.; Um, K. Control of synapse development and plasticity by Rho GTPase regulatory proteins. Prog. Neurobiol. 2011, 94, 133–148.
  20. Govek, E.-E.; Newey, S.E.; Van Aelst, L. The role of the Rho GTPases in neuronal development. Genome Res. 2005, 19, 1–49.
  21. Heasman, S.J.; Ridley, A.J. Mammalian Rho GTPases: new insights into their functions from in vivo studies. Nat. Rev. Mol. Cell Biol. 2008, 9, 690–701.
  22. Hodge, R.G.; Ridley, A.J. Regulating Rho GTPases and their regulators. Nat. Rev. Mol. Cell Boil. 2016, 17, 496–510.
  23. Bai, Y.; Xiang, X.; Liang, C.; Shi, L. Regulating Rac in the Nervous System: Molecular Function and Disease Implication of Rac GEFs and GAPs. BioMed. Res. Int. 2015, 2015, 632450.
  24. Fort, P.; Blangy, A. The Evolutionary Landscape of Dbl-Like RhoGEF Families: Adapting Eukaryotic Cells to Environmental Signals. Genome Biol. Evol. 2017, 9, 1471–1486.
  25. Rossman, K.L.; Der, C.J.; Sondek, J. GEF means go: Turning on RHO GTPases with guanine nucleotide-exchange factors. Nat. Rev. Mol. Cell Biol. 2005, 6, 167–180.
  26. Amin, E.; Jaiswal, M.; Derewenda, U.; Reis, K.; Nouri, K.; Koessmeier, K.T.; Aspenström, P.; Somlyo, A.V.; Dvorsky, R.; Ahmadian, M.R. Deciphering the Molecular and Functional Basis of RHOGAP Family Proteins. J. Biol. Chem. 2016, 291, 20353–20371.
  27. Bustelo, X.R.; Sauzeau, V.; Berenjeno, I.M. GTP-binding proteins of the Rho/Rac family: Regulation, effectors and functions in vivo. BioEssays 2007, 29, 356–370.
  28. Edwards, D.C.; Sanders, L.C.; Bokoch, G.M.; Gill, G.N. Activation of LIM-kinase by Pak1 couples Rac/Cdc42 GTPase signalling to actin cytoskeletal dynamics. Nat. Cell Biol. 1999, 1, 253–259.
  29. Tahirovic, S.; Hellal, F.; Neukirchen, R.; Hindges, R.; Garvalov, B.K.; Flynn, K.C.; Stradal, T.; Chrostek-Grashoff, A.; Brakebusch, C.; Bradke, F. Rac1 Regulates Neuronal Polarization through the WAVE Complex. J. Neurosci. 2010, 30, 6930–6943.
  30. Kang, J.; Park, H.; Kim, E. IRSp53/BAIAP2 in dendritic spine development, NMDA receptor regulation, and psychiatric disorders. Neuropharmacology 2016, 100, 27–39.
  31. Mpey, S.; Davare, M.; Lasiek, A.; Fortin, D.; Ando, H.; Varlamova, O.; Obrietan, K.; Soderling, T.R.; Goodman, R.H.; Wayman, G.A. An activity-induced microRNA controls dendritic spine formation by regulating Rac1-PAK signaling. Mol. Cell. Neurosci. 2009, 43, 146–156.
  32. Reijnders, M.R.; Ansor, N.M.; Kousi, M.; Yue, W.W.; Tan, P.L.; Clarkson, K.; Clayton-Smith, J.; Corning, K.; Jones, J.R.; Lam, W.W.; et al. RAC1 Missense Mutations in Developmental Disorders with Diverse Phenotypes. Am. J. Hum. Genet. 2017, 101, 466–477.
  33. Bolis, A.; Corbetta, S.; Cioce, A.; De Curtis, I. Differential distribution of Rac1 and Rac3 GTPases in the developing mouse brain: implications for a role of Rac3 in Purkinje cell differentiation. Eur. J. Neurosci. 2003, 18, 2417–2424.
  34. Tanabe, K.; Tachibana, T.; Yamashita, T.; Che, Y.H.; Yoneda, Y.; Ochi, T.; Tohyama, M.; Yoshikawa, H.; Kiyama, H. The Small GTP-Binding Protein TC10 Promotes Nerve Elongation in Neuronal Cells, and Its Expression Is induced during Nerve Regeneration in Rats. J. Neurosci. 2000, 20, 4138–4144.
  35. Corbetta, S.; Gualdoni, S.; Albertinazzi, C.; Paris, S.; Croci, L.; Consalez, G.G.; De Curtis, I. Generation and Characterization of Rac3 Knockout Mice. Mol. Cell. Biol. 2005, 25, 5763–5776.
  36. Sugihara, K.; Nakatsuji, N.; Nakamura, K.; Nakao, K.; Hashimoto, R.; Otani, H.; Sakagami, H.; Kondo, H.; Nozawa, S.; Aiba, A.; et al. Rac1 is required for the formation of three germ layers during gastrulation. Oncogene 1998, 17, 3427–3433.
  37. Chen, L.; Liao, G.; Waclaw, R.R.; Burns, K.A.; Linquist, D.; Campbell, K.; Zheng, Y.; Kuan, C.-Y. Rac1 Controls the Formation of Midline Commissures and the Competency of Tangential Migration in Ventral Telencephalic Neurons. J. Neurosci. 2007, 27, 3884–3893.
  38. Chen, L.; Melendez, J.; Campbell, K.; Kuan, C.-Y.; Zheng, Y. Rac1 deficiency in the forebrain results in neural progenitor reduction and microcephaly. Dev. Biol. 2009, 325, 162–170.
  39. Hua, Z.L.; Emiliani, F.E.; Nathans, J. Rac1 plays an essential role in axon growth and guidance and in neuronal survival in the central and peripheral nervous systems. Neural Dev. 2015, 10, 21.
  40. Vidaki, M.; Tivodar, S.; Doulgeraki, K.; Tybulewicz, V.L.; Kessaris, N.; Pachnis, V.; Karagogeos, D. Rac1-Dependent Cell Cycle Exit of MGE Precursors and GABAergic Interneuron Migration to the Cortex. Cereb. Cortex 2011, 22, 680–692.
  41. Haditsch, U.; Leone, D.P.; Farinelli, M.; Chrostek-Grashoff, A.; Brakebusch, C.; Mansuy, I.M.; McConnell, S.K.; Palmer, T.D. A central role for the small GTPase Rac1 in hippocampal plasticity and spatial learning and memory. Mol. Cell. Neurosci. 2009, 41, 409–419.
  42. Haditsch, U.; Anderson, M.P.; Freewoman, J.; Cord, B.; Babu, H.; Brakebusch, C.; Palmer, T.D. Neuronal Rac1 is required for learning-evoked neurogenesis. J. Neurosci. 2013, 33, 12229–12241.
  43. Pennucci, R.; Talpo, F.; Astro, V.; Montinaro, V.; Morè, L.; Cursi, M.; Castoldi, V.; Chiaretti, S.; Bianchi, V.; Marenna, S.; et al. Loss of Either Rac1 or Rac3 GTPase Differentially Affects the Behavior of Mutant Mice and the Development of Functional GABAergic Networks. Cereb. Cortex 2016, 26, 873–890.
  44. Takai, Y.; Sasaki, T.; Matozaki, T. Small GTP-binding proteins. Physiol. Rev. 2001, 81, 153–208.
  45. Kitamura, Y.; Kitamura, T.; Sakaue, H.; Maeda, T.; Ueno, H.; Nishio, S.; Ohno, S.; Osada, S.i.; Sakaue, M.; Ogawa, W.; et al. Interaction of Nck-associated protein 1 with activated GTP-binding protein Rac. Biochem. J. 1997, 322 Pt 3, 873–878.
  46. Iossifov, I.; Ronemus, M.; Levy, D.; Wang, Z.; Hakker, I.; Rosenbaum, J.; Yamrom, B.; Lee, Y.-h.; Narzisi, G.; Leotta, A.; et al. De Novo Gene Disruptions in Children on the Autistic Spectrum. Neuron 2012, 74, 285–299.
  47. De Rubeis, S.; He, X.; Goldberg, A.P.; Poultney, C.S.; E Samocha, K.; Cicek, A.E.; Kou, Y.; Liu, L.; Fromer, M.; Singh, T.; et al. Synaptic, transcriptional and chromatin genes disrupted in autism. Nature 2014, 515, 209–215.
  48. Iossifov, I.; O’Roak, B.J.; Sanders, S.J.; Ronemus, M.; Krumm, N.; Levy, D.; Stessman, H.A.; Witherspoon, K.T.; Vives, L.; Patterson, K.E.; et al. The contribution of de novo coding mutations to autism spectrum disorder. Nature 2014, 515, 216–221.
  49. Iossifov, I.; Levy, D.; Allen, J.; Ye, K.; Ronemus, M.; Lee, Y.-h.; Yamrom, B.; Wigler, M. Low load for disruptive mutations in autism genes and their biased transmission. Proc. Natl. Acad. Sci. United States Am. 2015, 112, E5600–E5607.
  50. Wang, T.; Guo, H.; Xiong, B.; Stessman, H.A.; Wu, H.; Coe, B.P.; Turner, T.; Liu, Y.; Zhao, W.; Hoekzema, K.; et al. De novo genic mutations among a Chinese autism spectrum disorder cohort. Nat. Commun. 2016, 7, 13316.
  51. Freed, D.; Pevsner, J. The Contribution of Mosaic Variants to Autism Spectrum Disorder. PLoS Genet. 2016, 12, e1006245.
  52. Kitamura, T.; Kitamura, Y.; Yonezawa, K.; Totty, N.F.; Gout, I.; Hara, K.; Waterfield, M.D.; Sakaue, M.; Ogawa, W.; Kasuga, M. Molecular cloning of p125Nap1, a protein that associates with an SH3 domain of Nck. Biochem. Biophys. Res. Commun. 1996, 219, 509–514.
  53. Suzuki, T.; Nishiyama, K.; Yamamoto, A.; Inazawa, J.; Iwaki, T.; Yamada, T.; Kanazawa, I.; Sakaki, Y. Molecular cloning of a novel apoptosis-related gene, human Nap1 (NCKAP1), and its possible relation to Alzheimer disease. Genomics 2000, 63, 246–254.
  54. Yokota, Y.; Ring, C.; Cheung, R.; Pevny, L.; Anton, E.S. Nap1-regulated neuronal cytoskeletal dynamics is essential for the final differentiation of neurons in cerebral cortex. Neuron 2007, 54, 429–445.
  55. Ren, J.; Wen, L.; Gao, X.; Jin, C.; Xue, Y.; Yao, X. DOG 1.0: illustrator of protein domain structures. Cell Res. 2009, 19, 271–273.
  56. Doornbos, M.; Sikkema-Raddatz, B.; Ruijvenkamp, C.A.L.; Dijkhuizen, T.; Bijlsma, E.K.; Gijsbers, A.C.J.; Hilhorst-Hofstee, Y.; Hordijk, R.; Verbruggen, K.T.; Kerstjens-Frederikse, W.S.; et al. Nine patients with a microdeletion 15q11.2 between breakpoints 1 and 2 of the Prader-Willi critical region, possibly associated with behavioural disturbances. Eur. J. Med. Genet. 2009, 52, 108–115.
  57. Van der Zwaag, B.; Staal, W.G.; Hochstenbach, R.; Poot, M.; Spierenburg, H.A.; de Jonge, M.V.; Verbeek, N.E.; van’t Slot, R.; van Es, M.A.; Staal, F.J.; et al. A Co-segregating Microduplication of Chromosome 15q11.2 Pinpoints Two Risk Genes for Autism Spectrum Disorder. Am. J. Med. Genet. Part B Neuropsychiatr. Genet. 2010, 153B, 960–966.
  58. Picinelli, C.; Lintas, C.; Piras, I.S.; Gabriele, S.; Sacco, R.; Brogna, C.; Persico, A.M. Recurrent 15q11.2 BP1-BP2 Microdeletions and Microduplications in the Etiology of Neurodevelopmental Disorders. Am. J. Med. Genet. Part B Neuropsychiatr. Genet. 2016, 171, 1088–1098.
  59. Cox, D.M.; Butler, M.G. The 15q11.2 BP1-BP2 Microdeletion Syndrome: A Review. Int. J. Mol. Sci. 2015, 16, 4068–4082.
  60. Leblond, C.S.; Heinrich, J.; Delorme, R.; Proepper, C.; Betancur, C.; Huguet, G.; Konyukh, M.; Chaste, P.; Ey, E.; Rastam, M.; et al. Genetic and functional analyses of SHANK2 mutations suggest a multiple hit model of autism spectrum disorders. PLoS Genet. 2012, 8, e1002521.
  61. Isabel Alvarez-Mora, M.; Calvo Escalona, R.; Puig Navarro, O.; Madrigal, I.; Quintela, I.; Amigo, J.; Martinez-Elurbe, D.; Linder-Lucht, M.; Aznar Lain, G.; Carracedo, A.; et al. Comprehensive molecular testing in patients with high functioning autism spectrum disorder. Mutat. Res. Fundam. Mol. Mech. Mutagenesis 2016, 784, 46–52.
  62. Waltes, R.; Duketis, E.; Knapp, M.; Anney, R.J.L.; Huguet, G.; Schlitt, S.; Jarczok, T.A.; Sachse, M.; Kaempfer, L.M.; Kleinboeck, T.; et al. Common variants in genes of the postsynaptic FMRP signalling pathway are risk factors for autism spectrum disorders. Hum. Genet. 2014, 133, 781–792.
  63. Toma, C.; Torrico, B.; Hervas, A.; Valdes-Mas, R.; Tristan-Noguero, A.; Padillo, V.; Maristany, M.; Salgado, M.; Arenas, C.; Puente, X.S.; et al. Exome sequencing in multiplex autism families suggests a major role for heterozygous truncating mutations. Mol. Psychiatry 2014, 19, 784–790.
  64. Wang, J.; Tao, Y.; Song, F.; Sun, Y.; Ott, J.; Saffen, D. Common Regulatory Variants of CYFIP1 Contribute to Susceptibility for Autism Spectrum Disorder (ASD) and Classical Autism. Ann. Hum. Genet. 2015, 79, 329–340.
  65. Noroozi, R.; Omrani, M.D.; Sayad, A.; Taheri, M.; Ghafouri-Fard, S. Cytoplasmic FMRP interacting protein 1/2 (CYFIP1/2) expression analysis in autism. Metab. Brain Dis. 2018, 33, 1353–1358.
  66. Kobayashi, K.; Kuroda, S.; Fukata, M.; Nakamura, T.; Nagase, T.; Nomura, N.; Matsuura, Y.; Yoshida-Kubomura, N.; Iwamatsu, A.; Kaibuchi, K. p140Sra-1 (specifically Rac1-associated protein) is a novel specific target for Rac1 small GTPase. J. Biol. Chem. 1998, 273, 291–295.
  67. De Rubeis, S.; Pasciuto, E.; Li, K.W.; Fernandez, E.; Di Marino, D.; Buzzi, A.; Ostroff, L.E.; Klann, E.; Zwartkruis, F.J.T.; Komiyama, N.H.; et al. CYFIP1 Coordinates mRNA Translation and Cytoskeleton Remodeling to Ensure Proper Dendritic Spine Formation. Neuron 2013, 79, 1169–1182.
  68. Koster, F.; Schinke, B.; Niemann, S.; Hermans-Borgmeyer, I. Identification of shyc, a novel gene expressed in the murine developing and adult nervous system. Neurosci. Lett. 1998, 252, 69–71.
  69. Bonaccorso, C.M.; Spatuzza, M.; Di Marco, B.; Gloria, A.; Barrancotto, G.; Cupo, A.; Musumeci, S.A.; D’Antoni, S.; Bardoni, B.; Catania, M.V. Fragile X mental retardation protein (FMRP) interacting proteins exhibit different expression patterns during development. Int. J. Dev. Neurosci. 2015, 42, 15–23.
  70. Bozdagi, O.; Sakurai, T.; Dorr, N.; Pilorge, M.; Takahashi, N.; Buxbaum, J.D. Haploinsufficiency of Cyfip1 produces fragile X-like phenotypes in mice. PLoS ONE 2012, 7, e42422.
  71. Hsiao, K.; Harony-Nicolas, H.; Buxbaum, J.D.; Bozdagi-Gunal, O.; Benson, D.L. Cyfip1 Regulates Presynaptic Activity during Development. J. Neurosci. 2016, 36, 1564–1576.
  72. Pathania, M.; Davenport, E.C.; Muir, J.; Sheehan, D.F.; López-Doménech, G.; Kittler, J.T. The autism and schizophrenia associated gene CYFIP1 is critical for the maintenance of dendritic complexity and the stabilization of mature spines. Transl. Psychiatry 2014, 4, e374.
  73. Bachmann, S.O.; Sledziowska, M.; Cross, E.; Kalbassi, S.; Waldron, S.; Chen, F.; Ranson, A.; Baudouin, S.J. Behavioral training rescues motor deficits in Cyfip1 haploinsufficiency mouse model of autism spectrum disorders. Transl. Psychiatry 2019, 9, 29.
  74. Chung, L.; Wang, X.; Zhu, L.; Towers, A.J.; Cao, X.; Kim, I.H.; Jiang, Y.-H. Parental origin impairment of synaptic functions and behaviors in cytoplasmic FMRP interacting protein 1 (Cyfip1) deficient mice. Brain Res. 2015, 1629, 340–350.
  75. Domínguez-Iturza, N.; Lo, A.C.; Shah, D.; Armendáriz, M.; Vannelli, A.; Mercaldo, V.; Trusel, M.; Li, K.W.; Gastaldo, D.; Santos, A.R.; et al. The autism- and schizophrenia-associated protein CYFIP1 regulates bilateral brain connectivity and behaviour. Nat. Commun. 2019, 10, 3454.
  76. Davenport, E.C.; Szulc, B.R.; Drew, J.; Taylor, J.; Morgan, T.; Higgs, N.F.; Lopez-Domenech, G.; Kittler, J.T. Autism and Schizophrenia-Associated CYFIP1 Regulates the Balance of Synaptic Excitation and Inhibition. Cell Rep. 2019, 26, 2037.
  77. Silva, A.I.; Haddon, J.E.; Ahmed Syed, Y.; Trent, S.; Lin, T.-C.E.; Patel, Y.; Carter, J.; Haan, N.; Honey, R.C.; Humby, T.; et al. Cyfip1 haploinsufficient rats show white matter changes, myelin thinning, abnormal oligodendrocytes and behavioural inflexibility. Nat. Commun. 2019, 10, 3455.
  78. Fricano-Kugler, C.; Gordon, A.; Shin, G.; Gao, K.; Nguyen, J.; Berg, J.; Starks, M.; Geschwind, D.H. CYFIP1 overexpression increases fear response in mice but does not affect social or repetitive behavioral phenotypes. Mol. Autism 2019, 10, 25.
  79. Papadopoulos, T.; Korte, M.; Eulenburg, V.; Kubota, H.; Retiounskaia, M.; Harvey, R.J.; Harvey, K.; O’Sullivan, G.A.; Laube, B.; Hülsmann, S.; et al. Impaired GABAergic transmission and altered hippocampal synaptic plasticity in collybistin-deficient mice. EMBO J. 2007, 26, 3888–3899.
  80. Zong, W.; Liu, S.; Wang, X.; Zhang, J.; Zhang, T.; Liu, Z.; Wang, N.; Zhang, A.; Zhu, M.; Gao, J. Trio gene is required for mouse learning ability. Brain Res. 2015, 1608, 82–90.
  81. Katrancha, S.M.; Shaw, J.E.; Zhao, A.Y.; Myers, S.A.; Cocco, A.R.; Jeng, A.T.; Zhu, M.; Pittenger, C.; Greer, C.A.; Carr, S.A.; et al. Trio Haploinsufficiency Causes Neurodevelopmental Disease-Associated Deficits. Cell Rep. 2019, 26, 2805–2817.e9.
  82. Li, J.; Chai, A.; Wang, L.; Ma, Y.; Wu, Z.; Yu, H.; Mei, L.; Lu, L.; Zhang, C.; Yue, W.; et al. Synaptic P-Rex1 signaling regulates hippocampal long-term depression and autism-like social behavior. Proc. Natl. Acad. Sci. USA 2015, 112, E6964–E6972.
  83. Lu, D.-H.; Liao, H.-M.; Chen, C.-H.; Tu, H.-J.; Liou, H.-C.; Gau, S.S.-F.; Fu, W.-M. Impairment of social behaviors in Arhgef10 knockout mice. Mol. Autism 2018, 9, 11.
  84. Guo, D.; Peng, Y.; Wang, L.; Sun, X.; Wang, X.; Liang, C.; Yang, X.; Li, S.; Xu, J.; Ye, W.-C.; et al. Autism-like social deficit generated by Dock4 deficiency is rescued by restoration of Rac1 activity and NMDA receptor function. Mol. Psychiatry 2019.
  85. Khelfaoui, M.; Denis, C.; van Galen, E.; de Bock, F.; Schmitt, A.; Houbron, C.; Morice, E.; Giros, B.; Ramakers, G.; Fagni, L.; et al. Loss of X-linked mental retardation gene oligophrenin 1 in mice impairs spatial memory and leads to ventricular enlargement and dendritic spine immaturity. J. Neurosci. 2007, 27, 9439–9450.
  86. Meziane, H.; Khelfaoui, M.; Morello, N.; Hiba, B.; Calcagno, E.; Reibel-Foisset, S.; Selloum, M.; Chelly, J.; Humeau, Y.; Riet, F.; et al. Fasudil treatment in adult reverses behavioural changes and brain ventricular enlargement in Oligophrenin-1 mouse model of intellectual disability. Hum. Mol. Genet. 2016, 25, 2314–2323.
  87. Redolfi, N.; Galla, L.; Maset, A.; Murru, L.; Savoia, E.; Zamparo, I.; Gritti, A.; Billuart, P.; Passafaro, M.; Lodovichi, C. Oligophrenin-1 regulates number, morphology and synaptic properties of adult-born inhibitory interneurons in the olfactory bulb. Hum. Mol. Genet. 2016, 25, 5198–5211.
  88. Khelfaoui, M.; Gambino, F.; Houbaert, X.; Ragazzon, B.; Müller, C.; Carta, M.; Lanore, F.; Srikumar, B.N.; Gastrein, P.; Lepleux, M.; et al. Lack of the presynaptic RhoGAP protein oligophrenin1 leads to cognitive disabilities through dysregulation of the cAMP/PKA signalling pathway. Philos. Trans. R. Soc. Lond. B Biol. Sci. 2013, 369, 20130160.
  89. Zhang, C.-L.; Aime, M.; Laheranne, E.; Houbaert, X.; El Oussini, H.; Martin, C.; Lepleux, M.; Normand, E.; Chelly, J.; Herzog, E.; et al. Protein Kinase A Deregulation in the Medial Prefrontal Cortex Impairs Working Memory in Murine Oligophrenin-1 Deficiency. J. Neurosci. 2017, 37, 11114–11126.
  90. Nakamura, T.; Arima-Yoshida, F.; Sakaue, F.; Nasu-Nishimura, Y.; Takeda, Y.; Matsuura, K.; Akshoomoff, N.; Mattson, S.N.; Grossfeld, P.D.; Manabe, T.; et al. PX-RICS-deficient mice mimic autism spectrum disorder in Jacobsen syndrome through impaired GABAA receptor trafficking. Nat. Commun. 2016, 7, 10861.
  91. Nakamura, T.; Sakaue, F.; Nasu-Nishimura, Y.; Takeda, Y.; Matsuura, K.; Akiyama, T. The Autism-Related Protein PX-RICS Mediates GABAergic Synaptic Plasticity in Hippocampal Neurons and Emotional Learning in Mice. Ebiomedicine 2018, 34, 189–200.
  92. Carlson, B.R.; Lloyd, K.E.; Kruszewski, A.; Kim, I.-H.; Rodriguiz, R.M.; Heindel, C.; Faytell, M.; Dudek, S.M.; Wetsel, W.C.; Soderling, S.H. WRP/srGAP3 Facilitates the Initiation of Spine Development by an Inverse F-BAR Domain, and Its Loss Impairs Long-Term Memory. J. Neurosci. 2011, 31, 2447–2460.
  93. Waltereit, R.; Leimer, U.; Halbach, O.v.B.U.; Panke, J.; Hoelter, S.M.; Garrett, L.; Wittig, K.; Schneider, M.; Schmitt, C.; Calzada-Wack, J.; et al. Srgap3(-/-) mice present a neurodevelopmental disorder with schizophrenia-related intermediate phenotypes. FASEB J. 2012, 26, 4418–4428.
  94. Bertram, J.; Koschuetzke, L.; Pfannmoeller, J.P.; Esche, J.; van Diepen, L.; Kuss, A.W.; Hartmann, B.; Bartsch, D.; Lotze, M.; van Halbach, O.B.U. Morphological and behavioral characterization of adult mice deficient for SrGAP3. Cell Tissue Res. 2016, 366, 1–11.
  95. Janne, P.A.; Suchy, S.F.; Bernard, D.; MacDonald, M.; Crawley, J.; Grinberg, A.; Wynshaw-Boris, A.; Westphal, H.; Nussbaum, R.L. Functional overlap between murine Inpp5b and Ocrl1 may explain why deficiency of the murine ortholog for OCRL1 does not cause Lowe syndrome in mice. J. Clin. Investig 1998, 101, 2042–2053.
  96. Festa, B.P.; Berquez, M.; Gassama, A.; Amrein, I.; Ismail, H.M.; Samardzija, M.; Staiano, L.; Luciani, A.; Grimm, C.; Nussbaum, R.L.; et al. OCRL deficiency impairs endolysosomal function in a humanized mouse model for Lowe syndrome and Dent disease. Hum. Mol. Genet. 2019, 28, 1931–1946.
  97. Wang, Y.; Zeng, C.; Li, J.; Zhou, Z.; Ju, X.; Xia, S.; Li, Y.; Liu, A.; Teng, H.; Zhang, K.; et al. PAK2 Haploinsufficiency Results in Synaptic Cytoskeleton Impairment and Autism-Related Behavior. Cell Rep. 2018, 24, 2029–2041.
  98. Ogura, H.; Matsumoto, M.; Mikoshiba, K. Motor discoordination in mutant mice heterozygous for the type 1 inositol 1,4,5-trisphosphate receptor. Behav. Brain Res. 2001, 122, 215–219.
  99. Sugawara, T.; Hisatsune, C.; Le, T.D.; Hashikawa, T.; Hirono, M.; Hattori, M.; Nagao, S.; Mikoshiba, K. Type 1 Inositol Trisphosphate Receptor Regulates Cerebellar Circuits by Maintaining the Spine Morphology of Purkinje Cells in Adult Mice. J. Neurosci. 2013, 33, 12186.
  100. Hisatsune, C.; Miyamoto, H.; Hirono, M.; Yamaguchi, N.; Sugawara, T.; Ogawa, N.; Ebisui, E.; Ohshima, T.; Yamada, M.; Hensch, T.K.; et al. IP3R1 deficiency in the cerebellum/brainstem causes basal ganglia-independent dystonia by triggering tonic Purkinje cell firings in mice. Front. Neural Circuits 2013, 7, 156.
  101. Soderling, S.H.; Langeberg, L.K.; Soderling, J.A.; Davee, S.M.; Simerly, R.; Raber, J.; Scott, J.D. Loss of WAVE-1 causes sensorimotor retardation and reduced learning and memory in mice. Proc. Natl. Acad. Sci. USA 2003, 100, 1723–1728.
  102. Huang, M.; Liang, C.; Li, S.; Zhang, J.; Guo, D.; Zhao, B.; Liu, Y.; Peng, Y.; Xu, J.; Liu, W.; et al. Two Autism/Dyslexia Linked Variations of DOCK4 Disrupt the Gene Function on Rac1/Rap1 Activation, Neurite Outgrowth, and Synapse Development. Front. Cell. Neurosci. 2020, 13, 577.
  103. Yuen, R.K.C.; Merico, D.; Bookman, M.; Howe, J.L.; Thiruvahindrapuram, B.; Patel, R.V.; Whitney, J.; Deflaux, N.; Bingham, J.; Wang, Z.; et al. Whole genome sequencing resource identifies 18 new candidate genes for autism spectrum disorder. Nat. Neurosci. 2017, 20, 602.
  104. Willatt, L.; Cox, J.; Barber, J.; Cabanas, E.D.; Collins, A.; Donnai, D.; FitzPatrick, D.R.; Maher, E.; Martin, H.; Parnau, J.; et al. 3q29 Microdeletion syndrome: Clinical and molecular characterization of a new syndrome. Am. J. Hum. Genet. 2005, 77, 154–160.
  105. Quintero-Rivera, F.; Sharifi-Hannauer, P.; Martinez-Agosto, J.A. Autistic and Psychiatric Findings Associated With the 3q29 Microdeletion Syndrome: Case Report and Review. Am. J. Med Genet. Part A 2010, 152A, 2459–2467.
  106. Glassford, M.R.; Rosenfeld, J.A.; Freedman, A.A.; Zwick, M.E.; Mulle, J.G. Novel features of 3q29 deletion syndrome: Results from the 3q29 registry. Am. J. Med Genet. Part A 2016, 170, 999–1006.
  107. Jaffer, Z.M.; Chernoff, J. p21-activated kinases: three more join the Pak. Int. J. Biochem. Cell Biol. 2002, 34, 713–717.
  108. Rane, C.K.; Minden, A. P21 activated kinases: structure, regulation, and functions. Small Gtpases 2014, 5, e28003.
  109. Kreis, P.; Barnier, J.-V. PAK signalling in neuronal physiology. Cell. Signal. 2009, 21, 384–393.
  110. Arias-Romero, L.E.; Chernoff, J. A tale of two Paks. Biol. Cell 2008, 100, 97–108.
  111. Hofmann, C.; Shepelev, M.; Chernoff, J. The genetics of Pak. J. Cell Sci. 2004, 117, 4343–4354.
  112. Marlin, J.W.; Chang, Y.-W.E.; Ober, M.; Handy, A.; Xu, W.; Jakobi, R. Functional PAK-2 knockout and replacement with a caspase cleavage-deficient mutant in mice reveals differential requirements of full-length PAK-2 and caspase-activated PAK-2p34. Mamm. Genome 2011, 22, 306–317.
  113. Guo, H.; Wang, T.; Wu, H.; Long, M.; Coe, B.P.; Li, H.; Xun, G.; Ou, J.-J.; Chen, B.; Duan, G.; et al. Inherited and multiple de novo mutations in autism/developmental delay risk genes suggest a multifactorial model. Mol. Autism 2018, 9, 64.
  114. Geisheker, M.R.; Heymann, G.; Wang, T.; Coe, B.P.; Turner, T.N.; Stessman, H.A.F.; Hoekzema, K.; Kvarnung, M.; Shaw, M.; Friend, K.; et al. Hotspots of missense mutation identify neurodevelopmental disorder genes and functional domains. Nat. Neurosci. 2017, 20, 1043.
  115. Patel, S.; Joseph, S.K.; Thomas, A.P. Molecular properties of inositol 1,4,5-trisphosphate receptors. Cell Calcium 1999, 25, 247–264.
  116. Rosemblit, N.; Moschella, M.C.; Ondriasova, E.; Gutstein, D.E.; Ondrias, K.; Marks, A.R. Intracellular calcium release channel expression during embryogenesis. Dev. Biol. 1999, 206, 163–177.
  117. Nakanishi, S.; Maeda, N.; Mikoshiba, K. Immunohistochemical localization of an inositol 1,4,5-trisphosphate receptor, P400, in neural tissue: studies in developing and adult mouse brain. J. Neurosci. 1991, 11, 2075–2086.
  118. Taylor, C.W.; Genazzani, A.A.; Morris, S.A. Expression of inositol trisphosphate receptors. Cell Calcium 1999, 26, 237–251.
  119. Matsumoto, M.; Nakagawa, T.; Inoue, T.; Nagata, E.; Tanaka, K.; Takano, H.; Minowa, O.; Kuno, J.; Sakakibara, S.; Yamada, M.; et al. Ataxia and epileptic seizures in mice lacking type 1 inositol 1,4,5-trisphosphate receptor. Nature 1996, 379, 168–171.
  120. Inoue, T.; Kato, K.; Kohda, K.; Mikoshiba, K. Type 1 inositol 1,4,5-trisphosphate receptor is required for induction of long-term depression in cerebellar Purkinje neurons. J. Neurosci. 1998, 18, 5366–5373.
  121. Fujii, S.; Matsumoto, M.; Igarashi, K.; Kato, H.; Mikoshiba, K. Synaptic plasticity in hippocampal CA1 neurons of mice lacking type 1 inositol-1,4,5-trisphosphate receptors. Learn. Mem. 2000, 7, 312–320.
  122. Nagase, T.; Ito, K.I.; Kato, K.; Kaneko, K.; Kohda, K.; Matsumoto, M.; Hoshino, A.; Inoue, T.; Fujii, S.; Kato, H.; et al. Long-term potentiation and long-term depression in hippocampal CA1 neurons of mice lacking the IP3 type 1 receptor. Neuroscience 2003, 117, 821–830.
  123. Steinberg, S.F. Structural basis of protein kinase C isoform function. Physiol. Rev. 2008, 88, 1341–1378.
  124. Singh, R.K.; Kumar, S.; Gautam, P.K.; Tomar, M.S.; Verma, P.K.; Singh, S.P.; Kumar, S.; Acharya, A. Protein kinase C-alpha and the regulation of diverse cell responses. Biomol. Concepts 2017, 8, 143–153.
  125. Shuntoh, H.; Sakamoto, N.; Matsuyama, S.; Saitoh, M.; Tanaka, C. Molecular structure of the C beta catalytic subunit of rat cAMP-dependent protein kinase and differential expression of C alpha and C beta isoforms in rat tissues and cultured cells. Biochim. Et Biophys. Acta 1992, 1131, 175–180.
  126. Letiges, M.; Plomann, M.; Standaert, M.L.; Bandyopadhyay, G.; Sajan, M.P.; Kanoh, Y.; Farese, R.V. Knockout of PKC alpha enhances insulin signaling through PI3K. Mol. Endocrinol. 2002, 16, 847–858.
  127. Ito, Y.; Carss, K.J.; Duarte, S.T.; Hartley, T.; Keren, B.; Kurian, M.A.; Marey, I.; Charles, P.; Mendonca, C.; Nava, C.; et al. De Novo Truncating Mutations in WASF1 Cause Intellectual Disability with Seizures. Am. J. Hum. Genet. 2018, 103, 144–153.
  128. Benachenhou, N.; Massy, I.; Vacher, J. Characterization and expression analyses of the mouse Wiskott-Aldrich syndrome protein (WASP) family member Wave1/Scar. Gene 2002, 290, 131–140.
  129. Suetsugu, S.; Miki, H.; Takenawa, T. Identification of two human WAVE/SCAR homologues as general actin regulatory molecules which associate with the Arp2/3 complex. Biochem. Biophys. Res. Commun. 1999, 260, 296–302.
  130. Dahl, J.P.; Wang-Dunlop, J.; Gonzalez, C.; Goad, M.E.P.; Mark, R.J.; Kwak, S.P. Characterization of the WAVE1 knock-out mouse: Implications for CNS development. J. Neurosci. 2003, 23, 3343–3352.
  131. Ceglia, I.; Lee, K.-W.; Cahill, M.E.; Graves, S.M.; Dietz, D.; Surmeier, D.J.; Nestler, E.J.; Nairn, A.C.; Greengard, P.; Kim, Y. WAVE1 in neurons expressing the D1 dopamine receptor regulates cellular and behavioral actions of cocaine. Proc. Natl. Acad. Sci. USA 2017, 114, 1395–1400.
Subjects: Cell Biology
Contributor MDPI registered users' name will be linked to their SciProfiles pages. To register with us, please refer to :
View Times: 248
Revisions: 2 times (View History)
Update Date: 02 Jun 2021